Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A fibrolamellar carcinoma that is characterized by the presence of both pure fibrolamellar hepatocellular carcinoma and and conventional hepatocellular carcinoma components.
Biomarker and diagnostic research for mixed fibrolamellar hepatocellular carcinoma has been reported in the published literature.
No clinical trials have been registered for mixed fibrolamellar hepatocellular carcinoma.
2 publications have been identified in PubMed for mixed fibrolamellar hepatocellular carcinoma. Research spans Diagnostic / Biomarker (50%) and Case Report / Case Series (50%).
Ozer G (2025). [PMID: 39961817](https://pubmed.ncbi.nlm.nih.gov/39961817/). *Pediatr Radiol*. [Diagnostic / Biomarker]
Woulfe F (2024). [PMID: 39357487](https://pubmed.ncbi.nlm.nih.gov/39357487/). *Int J Surg Case Rep*. [Case Report / Case Series]
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 8:44 AM UTC
AI-curated news mentioning mixed fibrolamellar hepatocellular carcinoma
Updated Sep 8, 2026
A recent study analyzes nine cases of fibrolamellar hepatocellular carcinoma, providing insights into its clinicopathological and molecular genetic characteristics. This research contributes to the understanding of this rare liver cancer.
A case report highlights refractory hyperammonemic encephalopathy as a paraneoplastic manifestation of fibrolamellar hepatocellular carcinoma. This discovery may enhance understanding of the neurological complications associated with this rare cancer.
A recent publication discusses the management strategies for rare primary liver cancers, specifically combined hepato-cholangiocarcinoma and fibrolamellar hepatocellular carcinoma. This research highlights the complexities and treatment considerations for these unique cancer types.